CClinicalTrials.gg
CompletedNCT06265922Updated Feb 19, 2025

Cerebellar RTMS in Patients with Multiple Sclerosis

An interventional study of High frequency repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Patients with Multiple Sclerosis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

To determine the efficacy of high frequency cerebellar repetitive transcranial magnetic stimulation on coordination in patients with multiple sclerosis.

Read the detailed description

Forty patients with multiple sclerosis suffering from ataxia less than five in EDSS score will be recruited from the outpatient clinic at Faculty of Physical Therapy as well as Kasr Al-Ainy Multiple Sclerosis unit (KAMSU), Cairo University. The study will be applied during the remission period. Patients will be assessed by Biodex balance system, Berg balance scale, Four square step test and Nine-Hole Peg Test to investigate coordination in both equilibrium and non-equilibrium. Patient will be divided into two groups.The study group will be treated by High frequecy cerebellar repetitive transcranial magnetic stimulation besides a tailored physiotherapy program, while the control group will be treated by Sham cerebellar repetitive transcranial magnetic stimulation with a tailored physiotherapy program as well. The treatment duration for each patient will take weeks.

02

Conditions studied

  • Patients with Multiple Sclerosis

Keywords

  • Patients with Multiple Sclerosis
  • Coordination
  • Transcranial magnetic stimulation
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's enrollment of 30 is below the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinically definite MS (relapsing, remitting and secondary progressive) patients
  • Patients who are medically stable and Free from relapses three months before
  • Ambulant patients without an assistive device and score less than 5 on the Kurtzke Expanded Disability Status Scale (EDSS)
  • Patients receiving their disease modifying drugs but no medication changing during the previous three months.
  • Patients who had MRI evidence of lesions in the cerebellum or in the cerebellar pedunculi.
  • Right handed patients.
  • Severity of ataxia range from 4 to 10 according to scale of assessment and rating ataxia (SARA).
  • Did not apply cerebellar transcranial magnetic stimulation before.

Exclusion criteria

Exclusion Criteria:

  • Any other neurological deficits or orthopedics abnormalities.
  • Ataxic manifestations for other cause rather than Multiple Sclerosis.
  • Other neurological manifestations (e.g. spasticity, visual loss)
  • Secondary musculoskeletal complication such as contractures or deformities. Cardiovascular, pulmonary, hepatic, renal, hemopoietic and thyroid diseases.
  • Pregnant women.
  • Addicted individuals.
  • Previous surgeries in the brain.
  • Any magnetic or metallic devices implanted (like cochlear implants) .
  • Psychotic deficits or history of epileptic seizures.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    High frequency cerebellar repetitive transcranial magnetic stimulation

    Twenty patients will be treated by high frequency repetitive transcranial magnetic stimulation (Hf-rTMS) targeting the cerebellum beside a tailored physical therapy program designed for the ataxic manifestation The protocol of rTMS included 6 sessions over 2 weeks. MagPro R20 device will be applied over midline of cerebellum using circular coil. Ten repetition rate in 40 trains with one inter train interval will be applied two times within the same session, 5 minutes rest in between Tailored physiotherapy program for ataxic manifestation will be applied for 10 days in the same 2 weeks

    Device: High frequency repetitive transcranial magnetic stimulation

  • Sham comparator
    Sham cerebellar repetitive transcranial magnetic stimulation

    Twenty patients will be treated by sham cerebellar rTMS with the same parameters, same duration 6 sessions over 2 weeks except the coil will not be on the middle of the cerebellum instead it will be perpendicular away from it. But the program of physiotherapy is the same

    Device: Sham repetitive transcranial magnetic stimulation

Interventions

  • DeviceHigh frequency repetitive transcranial magnetic stimulation

    High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.

    Also known as: Hf-rTMS

  • DeviceSham repetitive transcranial magnetic stimulation

    Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness

06

What researchers measure

Primary outcomes

  1. Biodex balance system

    Change of balance and stability index from baseline to 2 weeks after the beginning of intervention (when the score decreases, this means good)

    Time frame: 2 weeks after end of treatment

Secondary outcomes

  1. Berg balance scale

    Change of the balance score from baseline to two weeks after the beginning of the intervention ( the scale consists of 14 item. Minimum score for each item is 0 and maximum score is 4, to record the patient the summation of the 14 item is counted. And if the score is increasing this means good)

    Time frame: 2 weeks after end of treatment

  2. Nine-Hole Peg Test (9-HPT)

    Change of manual dexterity of both the dominant and non dominant hand from baseline to 2 weeks after the beginning of intervention

    Time frame: 2 weeks after end of treatment

  3. Four square step test (FSST)

    Change of dynamic balance and coordination from baseline to 2 weeks after the beginning of intervention

    Time frame: 2 weeks after end of treatment

07

Study locations

1 site
  • Faculty of physical therapy, Cairo University
    Giza, Dokki 12612, Egypt
08

References and documents

Publications

  • Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020 Feb;131(2):474-528. doi: 10.1016/j.clinph.2019.11.002. Epub 2020 Jan 1. Erratum In: Clin Neurophysiol. 2020 May;131(5):1168-1169. doi: 10.1016/j.clinph.2020.02.003. PubMed 31901449 ↗
  • Aloizou AM, Pateraki G, Anargyros K, Siokas V, Bakirtzis C, Liampas I, Nousia A, Nasios G, Sgantzos M, Peristeri E, Dardiotis E. Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis. Rev Neurosci. 2021 Feb 25;32(7):723-736. doi: 10.1515/revneuro-2020-0140. Print 2021 Nov 25. PubMed 33641274 ↗
  • Somaa FA, de Graaf TA, Sack AT. Transcranial Magnetic Stimulation in the Treatment of Neurological Diseases. Front Neurol. 2022 May 20;13:793253. doi: 10.3389/fneur.2022.793253. eCollection 2022. PubMed 35669870 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06265922
Lead sponsor
Cairo University
Responsible party
Hoda Zayed Abd Elraheem Mohamed (Assistant lecturer, Cairo University) — Principal investigator
First posted
Feb 20, 2024
Start date
Feb 18, 2024
Primary completion
Jul 17, 2024
Completion
Aug 5, 2024
Last update
Feb 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion